Common Stock, par value $0.001 per share
- Symbol
- APUS
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Apimeds Pharmaceuticals US, Inc.
APUSNYSE_AMERICANEQUITYCurrent
Other Events
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ─────────────────────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release issued by MindWave Innovations Inc. dated October 4, 2026 (BlockAssure). 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
Company context
We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apitox is currently marketed and sold by Apimeds Inc. (“Apimeds Korea”) in the South Korea as “Apitoxin.” Apimeds US is not associated with the market, sale and revenues generated from Apitoxin in South Korea, and Apitoxin has not been approved by the U.S. Food and Drug Administration (the “FDA”) for any indication. Apimeds is currently developing Apitox as a potential osteoarthritis (“OA”) treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 1, 2026
- Other EventsSep 29, 2026
- Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearSep 23, 2026
- Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
- Entry into a Material Definitive AgreementAug 21, 2026
Registered securities in this filing
Apimeds Pharmaceuticals US, Inc. · 8-K · Filed 2026-10-13
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Description
No.
───────────────────────────────────────────────────────────────────────────────────────────────────────
99.1 Press Release issued by MindWave Innovations Inc. dated October 4, 2026 (BlockAssure).
104 Cover
Page Interactive Data File (embedded within the inline XBRL document)
Filed exhibits (1)
Exhibit 99.1 MindWave Innovations Signs Agreement with US-Based BlockAssure to Build and Operate AssureChain, an End-to-End Insurance and Reinsurance Network AssureChain, a dedicated subnet of MindChain, will run every insurance function on-chain, while MindChain provides settlement and anchoring to Ethereum MATAWAN, New Jersey, Oct. 4, 2026 - via IBN - MindWave Innovations Inc. USA (“MindWave”), a wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ( NYSE American: APUS ), has signed a 2-year master maintenance and service agreement with Delaware-based BlockAssure Inc. (“BlockAssure”) to build, deploy and operate AssureChain, a dedicated subnet of MindChain that will run BlockAssure’s insurance and reinsurance operations on-chain. For MindWave, this is an important expansion of its U.S. business. It takes the company’s technology work into insurance and reinsurance, and it is a long-term build-and-operate contract with a U.S. client. “BlockAssure chose us to build AssureChain, and it is exactly the kind of work we want to do for U.S. clients,” said Dr. Vin Menon, Chief Executive Officer of MindWave Innovations Inc. USA. MindWave will design, develop, security-audit a…
Open exhibit ↗